Jacobus Pharmaceutical’s Ruzurgi (amifampridine) Receives the US FDA’s Approval for Lambert-Eaton myasthenic syndrome


  • The approval is based on the study assessing Ruzurgi vs PBO in 32 adult patients while patients taking Ruzurgi for at least three months prior to entering the study
  • The study measured effectiveness of a patient to rise from a chair, walk three meters & return to the chair for three consecutive laps without pause, self-assessment scale for LEMS-related weakness evaluating the feeling of weakening or strengthening which was more in PBO patients and patients experienced less impairment vs PBO
  • Ruzurgi tablets is a potassium chain blocker indicated for LEMS and has received FDA’s Priority Review and Fast Track designation as well as Orphan Drug Designations

Click here to read full press release/ article | Ref: Jacobus Pharmaceutical | Image: Signbox

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post